The cell transformation assay to assess potential carcinogenic properties of nanoparticles - Institut Agro Dijon Accéder directement au contenu
Article Dans Une Revue Mutation Research - Reviews Année : 2023

The cell transformation assay to assess potential carcinogenic properties of nanoparticles

The cell transformation assay to assess potential carcinogenic properties of nanoparticles.

Résumé

Nanoparticles (NPs) are present in many daily life products with particular physical-chemical properties (size, density, porosity, geometry …) giving very interesting technological properties. Their use is continuously growing and NPs represent a new challenge in terms of risk assessment, consumers being multi-exposed. Toxic effects have already been identified such as oxidative stress, genotoxicity, inflammatory effects, and immune reactions, some of which are leading to carcinogenesis. Cancer is a complex phenomenon implying multiple modes of action and key events, and prevention strategies in cancer include a proper assessment of the properties of NPs. Therefore, introduction of new agents like NPs into the market creates fresh regulatory challenges for an adequate safety evaluation and requires new tools. The Cell Transformation Assay (CTA) is an in vitro test able of highlighting key events of characteristic phases in the cancer process, initiation and promotion. This review presents the development of this test and its use with NPs. The article underlines also the critical issues to address for assessing NPs carcinogenic properties and approaches for improving its relevance.
Fichier non déposé

Dates et versions

hal-04044912 , version 1 (24-03-2023)

Identifiants

Citer

Ruzanna Hayrapetyan, Théo Lacour, Luce Annette, Francis Finot, Marie-Christine Chagnon, et al.. The cell transformation assay to assess potential carcinogenic properties of nanoparticles. Mutation Research - Reviews, 2023, 791, pp.108455. ⟨10.1016/j.mrrev.2023.108455⟩. ⟨hal-04044912⟩
14 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More